Johannes, C. B., Beachler, D. C., Layton, J. B., Danysh, H. E., Ziemiecki, R. ., Arana, A. ., … Gilsenan, A. . (2022). Post-Authorization Safety Study of Hospitalization for Acute Kidney Injury in Patients with Type 2 Diabetes Exposed to Dapagliflozin in a Real-World Setting. Drug Saf. http://doi.org/10.1007/s40264-022-01263-3
M. Pladevall-Vila
First name
M.
Last name
Pladevall-Vila
Danysh, H. E., Johannes, C. B., Beachler, D. C., Layton, J. B., Ziemiecki, R. ., Arana, A. ., … Gilsenan, A. . (2022). Post-Authorization Safety Studies of Acute Liver Injury and Severe Complications of Urinary Tract Infection in Patients with Type 2 Diabetes Exposed to Dapagliflozin in a Real-World Setting. Drug Saf. http://doi.org/10.1007/s40264-022-01262-4
Willame, C. ., Rosillon, D. ., Zima, J. ., Angelo, M. G., Stuurman, A. L., Vroling, H. ., … Baril, L. . (2016). Risk of new onset autoimmune disease in 9- to 25-year-old women exposed to human papillomavirus-16/18 AS04-adjuvanted vaccine in the United Kingdom. Hum Vaccin Immunother. http://doi.org/10.1080/21645515.2016.1199308
Cainzos-Achirica, M. ., Varas-Lorenzo, C. ., Pottegard, A. ., Asmar, J. ., Plana, E. ., Rasmussen, L. ., … Pladevall-Vila, M. . (2018). Methodological challenges when evaluating potential off-label prescribing of drugs using electronic health care databases: A case study of dabigatran etexilate in Europe. Pharmacoepidemiol Drug Saf. http://doi.org/10.1002/pds.4416